ATRS - Antares Pharma Inc


Strong Growth and ImprovingStock Price Attractive


based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 25.18%
Operating Income Growth is 100.5%
Net Income Growth is 583.41%
Earnings Per Share (EPS) Growth is 533.33%
Net Margin is 36.23%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 2.54
Debt Ratio is 0.35
Current Debt to Net Income Ratio is 0.54
Total Debt to Total Assets Ratio is 0.1
Cash Flow is MODERATE
Cash from Operations Growth is 161.56%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Antares Pharma Inc (ATRS) -
Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.
Exchange - NASDAQ
Industry - Surgical and Medical Instrument Manufacturing
Sector - Manufacturing
CEO - Robert Apple
Employees - 185

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.